Vertex’s ‘Slow Train To Pain’ R&D Rolls On

VX-548 Moves To Phase II

 
• By Sten Stovall
VX-548 is the most recent of Vertex's channel-blocking agents to enter the clinic • Source: Alamy

More from Clinical Trials

More from R&D